ICON and Medidata Join Forces to Bring New Productivity to Capturing Patient Voice in Clinical Trials

DUBLIN, IRELAND and NEW YORK, NY – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries and Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced a joint initiative designed to bring new efficiencies to the administration of electronic patient-reported outcomes (ePROs) in clinical trials. By combining Medidata's best-in-class technology with ICON's ready-to-use, pre-validated surveys, the new offering provides sponsors with an ePRO solution that reduces costs, saves time and enhances patient engagement.

Medidata Patient Cloud™, an innovative ePRO solution for patient-centric data capture, significantly simplifies trial setup through its configurable interface with the Medidata Clinical Cloud™. ICON brings ready-to-go, pre-validated patient input instruments for fast clinical trial deployment. These productivity enhancements, combined with the Patient Cloud interface available as a mobile app, create an industry-leading solution for capturing patient input in clinical research.

"We are pleased to extend our partnership with Medidata," commented Dermot Kenny, Executive Vice President, Global Clinical and Data Operations. "Their innovative technology, together with ICON's market-leading expertise, creates a solution that will help customers reduce study timelines and makes it easier for patients to record their experiences."

Available on any iOS® device and automatically unified with Medidata's platform, Patient Cloud provides electronic patient questionnaire and diary functionality in a model that simplifies the setup process, freeing research organizations from the burdens of custom software and proprietary devices. And in simplifying the data capture and patient participation processes, Medidata's ePRO solution is transforming the clinical trial experience for study participants at a time when capturing the patient voice is becoming increasingly important.

"We're thrilled to be expanding this partnership and share ICON's commitment to bringing the voice of the patient to clinical research," said Glen de Vries, Medidata's president. "Together, we're changing how the industry conducts clinical trials by making ePROs applicable to a wider array of studies, reducing the work required to use them and eliminating pain points such as equivalencies and other complicated processes."

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has approximately 11,000 employees, operating in 38 countries. 

About Medidata Solutions
Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations

Media Contacts 
Rebecca Power
Weber Shandwick
[email protected]

Gail Janowitz
Medidata Solutions
[email protected]

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.